Notice of concern (NOC) withdrawn for Matrix Laboratories Ltd.
M
Following corrective actions taken by Matrix Laboratories Ltd and the clarifications provided being
WHO Medicines Prequalification Programme statement regarding Ranbaxy, Paonta Sahib, India manufacturing site
M
WHO is aware of the recent actions taken by the USA Food and Drug Administration (FDA) against the Ranbaxy, Paonta Sahib, India manufacturing site.
Creation of new WHO Public Inspection Report (WHOPIR) section: Archived WHOPIRs
M
As changes in manufacturing sites and activities on sites may change, it is suggested that all users of the list of prequalified products and WHOPIRs verify with the manufacturers
Ranbaxy products relisted and new Aurobindo products included in WHO's list of prequalified medicines
M
see also: WHO Media Centre: http://www.who.int/entity/mediacentre/news/notes/2005/n